GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Total Current Liabilities

CPP (Cancer Prevention Pharmaceuticals) Total Current Liabilities : $9.40 Mil (As of Mar. 2016)


View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Cancer Prevention Pharmaceuticals's total current liabilities for the quarter that ended in Mar. 2016 was $9.40

Cancer Prevention Pharmaceuticals Total Current Liabilities Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Total Current Liabilities Chart

Cancer Prevention Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15
Total Current Liabilities
1.29 3.22 5.93

Cancer Prevention Pharmaceuticals Quarterly Data
Dec13 Dec14 Mar15 Sep15 Dec15 Mar16
Total Current Liabilities Get a 7-Day Free Trial 3.22 - 4.92 5.93 9.40

Cancer Prevention Pharmaceuticals Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Cancer Prevention Pharmaceuticals's Total Current Liabilities for the fiscal year that ended in Dec. 2015 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.75+0
+Other Current Liabilities+Current Deferred Liabilities
=2.692+0.485
=5.93

Cancer Prevention Pharmaceuticals's Total Current Liabilities for the quarter that ended in Mar. 2016 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=3.265+0
+Other Current Liabilities+Current Deferred Liabilities
=3.62+2.511
=9.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Cancer Prevention Pharmaceuticals Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Total Current Liabilities
Comparable Companies
NUVPF ADMD RSPI YBAO ULUR NRXCF ACUR LBLTF PUFXF BKIT RLMD IGC MYOS CBICF SBFM PVCT AQSZF PTLF AOLS APRI
Traded in Other Exchanges
N/A
Address
Website
http://www.canprevent.com
Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.

Cancer Prevention Pharmaceuticals Headlines